THER-33. TOCILIZUMAB AS A POTENTIAL NOVEL THERAPY IN PATIENTS DIAGNOSED WITH ADAMANTINOMATOUS CRANIOPHARYNGIOMA

Adamantinomatous craniopharyngioma (ACP) makes up between 6–8% of pediatric brain tumors and is the most common pediatric tumor arising in the sellar/suprasellar region of the brain. The 10-year survival for patients diagnosed with craniopharyngioma ranges between 64–92%, but given complicating fact...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Grob, Sydney, Donson, Andrew, Prince, Eric, Vijmasi, Trinka, Foreman, Nicholas, Dahl, Nathan, Vibhakar, Rajeev, Mirsky, David, Hankinson, Todd, Levy, Jean Mulcahy
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2019
Materias:
Translational Therapeutics
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477345/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz036.237
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares